Immuron Limited American Depositary Shares
IMRNStock
$1.13+3.85%52W
Market Cap$9.72M
P/E—
Div yield—
Beta1.22
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-37.79%
Price vs S&P 500 (4W)25.87%
VGM Score72.50
Market Capitalization$9.72M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMRNImmuron Limited American Depositary Shares | A | B | B | $1.13 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Immuron Ltd is a biopharmaceutical company specializing in polyclonal antibody therapeutics for gastrointestinal and enteric diseases. It markets Travelan for travelers' diarrhea prevention and Protectyn as an immune supplement, while advancing two clinical-stage candidates (IMM124-E and IMM529) toward commercialization. The company generates revenue primarily from Australia, the USA, and Canada through its hyper-immune products segment.